SciELO - Scientific Electronic Library Online

 
vol.38 issue4Breaking paradygms: axillary reduction mammoplastyMaxillary growth according to the severity of unilateral cleft lip and palate author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Cirugía Plástica Ibero-Latinoamericana

On-line version ISSN 1989-2055Print version ISSN 0376-7892

Abstract

LOBO BAILON, F. et al. Bleomycin sclerotherapy for low-flow vascular malformations: our experience and literature review. Cir. plást. iberolatinoam. [online]. 2012, vol.38, n.4, pp.341-347. ISSN 1989-2055.  https://dx.doi.org/10.4321/S0376-78922012000400005.

Vascular anomalies are common in children and can be divided into two categories, vascular tumours and vascular malformations: high-flow or low-flow. The latter can be treated in different ways such as lasertherapy, drainage, aspiration, surgery or sclerotherapy depending on the type and location of the lesion. Among the accepted sclerosing agents, bleomycin has proven good results in the treatment of this condition. Herein we present our experience in the treatment of low-flow vascular malformations with intralesional bleomycin injection. This is a retrospective, descriptive study with 30 patients presenting a low-flow vascular malformation treated with intralesional bleomycin injection. Our results are good or excellent in 22 patients and poor in the other 8. According to our case series and the consulted literature, sclerotherapy with intralesional bleomycin injection is an effective and safe treatment for low-flow vascular malformations.

Keywords : Vascular malformation; Angioma; Hemangioma; Sclerotherapy; Bleomycin.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License